Bristol Myers Squibb pulls the curtain on PhIII data to back Opdivo in the adjuvant setting
In its latest attempt to outshine Merck’s Keytruda, Bristol Myers Squibb says it has Phase III data to back Opdivo as an adjuvant treatment in patients with muscle-invasive urothelial carcinoma.
Bristol Myers Squibb says its PD-1 blockbuster came close to doubling the average length of time patients lived without disease recurrence, with a median disease-free survival of 21 months in the treatment arm and 10.9 months in the placebo arm. And for patients whose tumors express PD-L1 ≥1%, Opdivo reduced the risk of disease recurrence or death by 47%, according to BMS.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
